Compare Brunswick Corporation (BC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs Moderna, Inc. — how do they compare? Brunswick Corporation trades at $78.86 (market cap $5.28B), while Moderna, Inc. trades at $63.72 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 4.6× Brunswick Corporation's market cap, and Brunswick Corporation pays a 2.16% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| BC | MRNA | |
|---|---|---|
Market Cap | $5.28B | $24.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $81.80 |
52-Week Low | $58.75 | $22.36 |
Enterprise Value | $7.28B | $20.33B |
Dividend Yield | 2.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BC trades at $80.43, down 1.37% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $1.56 versus $1.19 estimated, and the company maintains a dividend payout. Despite negative net income margins and ROE, revenue trends show stabilization, and cash flow from operations remains positive at $562.10M for 2025.
The outlook is cautiously optimistic, driven by earnings beats and a consensus price target of $85.33, but risks include persistent unprofitability and high debt levels. Investors may find opportunity in the bullish technical setup and institutional buying, though margin pressures and competitive challenges warrant close monitoring.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
